Decent overview of the increasingly competitive nature of the cancer market. Interesting to see the Pfizers and GSKs of the world hopping in,
New Drugs for Cancer Could Soon Flood Market
Analysts at Merrill Lynch recently estimated that the market for cancer drugs would double to $50 billion a year in 2010, from $25 billion now. But because of increased competition, the sales potential for each drug would fall 21 percent to 32 percent by then. For many types of cancer, the analysts said, the number of drugs in the final phase of clinical trials exceeds the number already on the market.
Comments